Research programme: auto-inducer 2 inhibitors - BioLineRxAlternative Names: BL-6030; BL-6031; EDP-05
Latest Information Update: 26 Mar 2013
At a glance
- Originator Hebrew University of Jerusalem
- Developer BioLineRx
- Class Small molecules
- Mechanism of Action Autoinducer 2 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 01 Mar 2013 Discontinued - Preclinical for Bacterial infections in Israel (unspecified route)